• Protein disulfide isomerase (PDI) interacts with the aIIbb3 integrin on platelets • We generated PDI domain fragments and full-length PDI containing point mutations • PDI interacts with aIIbb3 through the b 0 domain, with the a and a 0 domains contributing • This is the first report demonstrating PDI binding to a native protein on intact cells
Essentials
• Protein disulfide isomerase (PDI) interacts with the aIIbb3 integrin on platelets • We generated PDI domain fragments and full-length PDI containing point mutations • PDI interacts with aIIbb3 through the b 0 domain, with the a and a 0 domains contributing • This is the first report demonstrating PDI binding to a native protein on intact cells
Summary. Background: Protein disulfide isomerase (PDI)
is an oxidoreductase consisting of four domains arranged in the order a-b-b 0 -a 0 with an x-linker between the b 0 and a 0 domains. PDI binds to a IIb b 3 integrin on activated platelets, and potentiates activation of this integrin through the C-terminal CGHC active-site motif. How PDI binds to platelet a IIb b 3 is unknown. Objective and methods: We used PDI domain fragments and full-length PDI containing point mutations to study inhibition of Alexa 488-labeled PDI binding to thrombin-activated platelets. The effect of the PDI variants on platelet aggregation was tested. Results: Only PDI fragments containing the b 0 domain bound to activated platelets. A double mutant of the b 0 domain had decreased binding, confirming the essential role of the b 0 domain. Addition of mutations in the a and a 0 domains further decreased binding, suggesting that these domains contribute to the interaction of PDI with platelets. The ability of the b 0 domain to interact directly with a IIb b 3 was demonstrated with surface plasmon resonance, with contributions from the a and a 0 domains. The abb 0 x PDI fragment that binds to platelets but lacks the critical C-terminal active site inhibited platelet aggregation and in vivo thrombosis. Moreover, site mutations in the a, b 0 and a 0 domains that resulted in partial binding to platelets partially recovered aggregation of PDI-null platelets. PDI mutants that did not bind showed no recovery. Conclusion: PDI functionally interacts with a IIb b 3 on platelets through the sub
Introduction
Protein disulfide isomerase (PDI) is the prototypic member of the PDI family of enzymes, which catalyze the oxidation, reduction and isomerization of disulfide bonds. Although originally characterized as an endoplasmic reticulum protein involved in the formation of disulfide bonds in nascent proteins, PDI also has a central role in hemostasis and thrombosis [1] [2] [3] . PDI is composed of four major domains, i.e. a, b, b 0 , and a 0 , plus an acidic Cterminal c extension and a 19 amino acid x-linker sequence between the b 0 and a 0 domains. The C-terminal CGHC active-site motif in the a 0 domain of PDI mediates activation of the platelet a IIb b 3 integrin, which is required for platelet aggregation and platelet accumulation in vivo [3] . The b 0 domain of PDI acts as the principal binding domain for peptides, although the a and a 0 domains contribute to binding to larger partner proteins [4] [5] [6] . The b domain does not contribute to the binding of peptides or non-native proteins [7] or to thiol-disulfide exchange reactions [8] , and the C-terminal c extension is not involved in substrate binding [5] .
Binding of PDI to platelet a IIb b 3 integrin has been studied by the use of pure proteins, a IIb b 3 expressed in cells, and intact platelets. With the use of surface plasmon resonance (SPR), PDI has been shown to directly interact with a IIb b 3 and with the b 3 subunit of a IIb b 3 [9, 10] . PDI binds to Mn 2+ -treated Chinese hamster ovary (CHO) cells that express a IIb b 3 or the a v b 3 platelet integrin, but not to CHO cells expressing P-selectin [9] . There is a low level of binding of PDI to non-activated platelets; however, PDI binding to platelets increases dramatically with platelet activation [3, 10] . PDI binding to thrombin-activated or Mn 2+ -treated mouse platelets lacking a IIb b 3 is decreased by~70% as compared with platelets from wild-type (WT) mice [3, 10] . Mn 2+ directly induces conformational changes in a IIb b 3 in the absence of platelet activation [11] , suggesting that PDI directly interacts with a IIb b 3 on platelets as it undergoes conformational changes [3] . Mutation of the Cys in the CGHC active sites of PDI does not affect the binding of PDI and a IIb b 3 [3, 10] , implying that specific substrate-binding sites on PDI mediate non-covalent binding.
The mechanism by which PDI binds to its substrates has been studied with both recombinant fragments of PDI and full-length PDI containing point mutations of selected amino acids. When fragments of PDI were used, the b 0 domain was found to be the principal binding site of PDI [7] . Whereas the b 0 domain was sufficient for PDI binding to small peptides, addition of either the ab or a 0 domains to the b 0 domain was required for binding to a larger 28 amino acid PDI substrate peptide of bovine pancreatic trypsin inhibitor, as well as to the PDI substrate, 'scrambled' RNase [7] . The b 0 xa 0 domains of human PDI were the minimal element required for binding to Ero1a in the oxidative folding pathway [12] . Binding of the b 0 -containing fragments of PDI to Ero1a directly correlated with the ability of these fragments to reactivate RNase in a reconstituted Ero1a-PDI oxidative folding system. The I272W mutation of the b 0 domain of full-length PDI had the greatest effect on abolishing PDI binding to small peptides, and decreased affinity for scrambled RNase [13] . PDI functions as the b-subunit in collagen prolyl 4-hydroxylase to form a2b2 tetramers with the collagen prolyl 4-hydroxylase a subunit, an interaction thought to mimic that of PDI with its substrates [4] . Studies using PDI fragments found that the minimum requirement for PDI to function as the subunit of collagen prolyl 4-hydroxylase was the presence of the b 0 and a 0 domains of PDI [14] . However, mutational studies showed that binding sites in the a, b 0 and a 0 domains contributed to the most efficient assembly of the collagen prolyl 4-hydroxylase tetramer [4] . We are not aware of any studies that have characterized PDI binding to a native protein substrate.
In this study, we used both fragments of PDI and PDI variants with mutations of selected amino acids to study binding of PDI to thrombin-activated platelets. Whereas there was a low level of binding of PDI to non-activated platelets, PDI binding dramatically increased with platelet activation. The b 0 domain had an essential role in both PDI binding and supporting platelet aggregation. However, the a and a 0 domains were required for both maximal binding and the ability of PDI to support platelet aggregation. As platelet a IIb b 3 is the principal binding partner for PDI on platelets [3, 9, 10] , these studies suggest that the a, b 0 and a 0 domains are needed for efficient binding to a IIb b 3 as it undergoes conformational changes associated with platelet activation. 
Materials and methods

Materials
Generation of PDI fragments and PDI mutants
Fragments of PDI were generated ( Fig. 2A) with the boundaries of the domains as described previously [16] . Different PDI mutants were also generated from a fulllength human PDI construct by site-directed mutagenesis with a QuickChange kit (Stratagene, Agilent, Santa Clara, CA, USA), and the mutated sequences were verified by DNA sequencing. Truncated or mutated constructs were synthesized with an N-terminal His tag (MHHHHHH) to facilitate purification, and subcloned into the pET30a vector. The plasmids were transformed into Escherichia coli BL21 (DE3) competent cells. A single colony was inoculated into LB medium containing kanamycin, and cultured at 37°C and 4,000 g for 15 min. The cells were harvested by centrifugation, and the pellets were lysed by sonication. The target proteins were purified by one-step purification with an Ni column. Fractions were pooled together and dialyzed against phosphate-buffered saline (PBS). The purified proteins were run on 4-20% SDS-PAGE gels, and the purity of the proteins was analyzed by Coomassie staining. The purity was > 85-90%. Protein concentrations were determined with the Bradford protein assay, with bovine serum albumin as a standard (Fig. S1) .
The point mutations in PDI that we used (Figs 3A and 4A) have been previously used to study PDI binding to other proteins [4, 17, 18] . With a variety of biophysical analyses, mutations in PDI proteins were shown not to cause significant alterations in PDI structure, with the exception of W111I, which resulted in a marginally different form than the WT protein [4] . The range of biophysical analyses used to screen for significant structural changes in the recombinant proteins included binding to somatostatin (a function of the b 0 domain), protease stability (proteinase K and V8 protease digestion), and circular dichroism spectra in the far-ultraviolet region [4] . We employed the W111I, F258W, I272W/A and L386W mutations in our studies (amino acids are numbered without the 17 amino acid signal peptide).
Flow cytometry studies on PDI binding to thrombinactivated human platelets Flow cytometry studies on human platelets were performed with platelet-rich plasma prepared and diluted in Tyrode's albumin buffer, with the concentration adjusted to 1 9 10 8 mL
À1
, as previously described [3] . To study Alexa 488-labeled PDI binding to platelets, thrombin (0.5 U mL À1 )-activated platelets were incubated with 250 nM Alexa 488-labeled PDI for 10 min. Platelets were then diluted with PBS, and fixed with 1% paraformaldehyde; the samples were then analyzed on a BD Bioscience Calibur flow cytometer, and the data were analyzed with CELLQUEST, BD Biosciences, San Jose, CA, USA. To study PDI binding to platelets, a 10-fold excess of unlabeled WT PDI, or fragments or mutants of PDI, were preincubated with activated platelets for 10 min prior to the addition of Alexa 488-labeled PDI. Inhibition of Alexa 488-labeled PDI binding by unlabeled PDI was taken as 100% inhibition, and was subtracted from the total Alexa 488-labeled PDI binding. for 2 min with a running buffer of 10 mM HEPES, 150 mM NaCl, 1 mM MnCl 2 , and 0.05% Tween-20. The dissociation constant was analyzed with Biacore 8K software.
Methods for the aggregation and secretion studies on human and mouse platelets, labeling of a IIb b 3 on platelets with MPB, intravital microscopy of laser-induced thrombosis of the cremaster muscle arterioles and the statistical analysis are given in the Supporting information (under Supplemental Methods).
Results
PDI binding assay
Thrombin-induced activation of platelets substantially increased binding of Alexa 488-labeled PDI as compared with binding to non-activated platelets (Fig. 1A) , as previously reported [3, 10] . Preincubating platelets with unlabeled WT PDI dose-dependently inhibited binding of Alexa 488-labeled PDI to thrombin-activated platelets, with~70% inhibition of binding at the highest dose (Fig. 1B) , suggesting that most of the Alexa 488-labeled PDI binding is specific. In subsequent experiments, a 10-fold excess of unlabeled PDI was used. To simplify the , or a five-fold, 10-fold or 25-fold excess of unlabeled full-length PDI for 10 min, and this was followed by incubation with Alexa-PDI for 10 min. Mean AE standard error of the mean, n = 3, **P < 0.01, **P < 0.001, ***P < 0.001
presentation of the data, the residual background binding of Alexa 488-labeled PDI was subtracted.
The b 0 domain of PDI is essential for PDI binding to thrombin-activated platelets To investigate the mechanisms by which PDI binds to a IIb b 3 on platelets, we used two recombinant fragments of PDI containing the b 0 domain of PDI (abb 0 x and b 0 xa 0 ), and two fragments lacking this domain (ab and a 0 c) ( Fig. S1 ; Fig. 2A ). The abb 0 x and b 0 xa 0 constructs substantially inhibited binding of Alexa 488-labeled PDI to activated platelets, whereas the PDI fragments lacking the b 0 domain did not inhibit binding (Fig. 2B) . The abb 0 x construct lacking the a 0 domain CGHC active-site motif that is critical for platelet aggregation [3] inhibited collagen-induced and thrombin-induced platelet aggregation and ATP release (Fig. 2C,D) . The ab construct lacking the b 0 domain did not inhibit aggregation or ATP secretion. The b 0 xa 0 construct containing both the b 0 binding site and the a 0 CGHC activesite motif also did not inhibit aggregation or ATP release. Together, these findings suggest that the b 0 domain of PDI has a functional role in PDI binding to platelets.
The a and a 0 domains of PDI contribute to binding of PDI to platelets
The above studies suggest that the b 0 domain of PDI is required for PDI binding to a IIb b 3 on platelets; however, other domains of PDI may also contribute to binding. To study the role of other domains of PDI in the binding to a IIb b 3 on activated platelets, we employed mutants of PDI that have been previously used to study the binding interactions of PDI with collagen prolyl 4-hydroxylase [4] and Ero1a [17, 18] (Fig. S2; Fig. 3A) . The I272W b 0 domain mutation abrogates PDI binding to small peptides [13] but not to collagen prolyl 4-hydroxylase [4] . Whereas the I272W b 0 mutation along with a single a or a 0 domain mutation (W111I/I272W or I272W/L386W) impaired the interaction of PDI with collagen prolyl 4-hydroxylase [4] , these mutants bound to platelets normally, because they completely inhibited the binding of Alexa 488-labeled PDI (Fig. 3B) . However, the W111I/ I272W/L386W triple mutant (with mutations in the a, b 0 and a 0 domains) only partially inhibited binding of Alexa 488-labeled PDI to the platelets. This suggests a role for the a and a 0 domains in the interaction of PDI with a IIb b 3 on activated platelets.
WT PDI fully recovered aggregation (and ATP secretion) of PDI-null platelets, whereas the W111I/I272W/L386W triple mutant, which partially bound to platelets (Fig. 3B) , partially recovered aggregation and secretion (Fig. 3C) . WT PDI also potentiated thrombin-induced platelet aggregation and secretion of human platelets (Fig. 3D) , as previously reported [3] . However, the weakly binding W111I/ I272W/L386W triple mutant did not show a significant effect (Fig. 3D) . Together, these findings suggest the a and a 0 domains contribute to PDI binding to platelets, and that this binding facilitates aggregation and secretion.
As the I272W mutation in the b 0 domain did not affect PDI binding to platelets (Fig. 3B) , we tested the F258W/ I272A double mutation (Fig. 4A ) of the b 0 domain, which interferes with PDI binding to Ero1a [17, 18] . The F258W/I272A double b 0 mutant partially inhibited binding of Alexa 488-labeled PDI to a similar extent as the W111I/I272W/L386W triple mutant (Fig. 4B) . The partial inhibition of Alexa 488-labeled PDI binding implies these two point mutations in the b 0 domain decrease the ability of PDI to bind to platelets. This provides additional evidence for the importance of the b 0 domain in PDI binding to platelets. The addition of the single a or a 0 mutation to the double b 0 mutation (W111I/F258W/I272A or F258W/ I272A/L386W) did not further affect PDI binding (Fig. 4A) . The addition of both the a and a 0 mutations to the b 0 domain mutations (W111I/F258W/I272A/L386W) fully abrogated PDI binding. These results confirm the importance of the a and a 0 domains in addition to the b 0 domain in binding of PDI to thrombin-activated platelets.
WT PDI recovered aggregation of PDI-null platelets, whereas the W111I/F258W/I272A/L386W mutant containing the a and a 0 mutations with the two b 0 mutations did not recover aggregation (Fig. 4C) . Similarly, WT PDI potentiated aggregation of human platelets, whereas the quadruple mutant did not (Fig. 4D) . These results suggest that binding of PDI to platelets involving the a, b 0 and a (Fig. 5A) was measured in one experiment, and a K d of 0.012 lM was measured in a separate experiment. The abb 0 x fragment, which binds to platelets and inhibits platelet aggregation (but lacks the a 0 binding site), bound with a K d of 0.059 lM (Fig. 5B ) (and 0.082 lM in a separate experiment). In contrast, the ab fragment, which lacks the b 0 domain, bound with a much higher K d , i.e. 6.7 lM (Fig. 5C) (and 8.2 lM) , whereas the W111I/F258W/ I272A/L386W mutant bound with a K d of 2.0 lM (Fig. 5D) (and 4.4 lM) . These results are consistent with the results of PDI binding to thrombin-activated platelets.
The direct binding of Alexa 647-labeled PDI to thrombin-activated platelets lacking a IIb b 3 was substantially decreased as compared with binding to WT platelets (Fig. S3A) , as previously described [3, 10] . Direct binding of the Alexa 647-labeled abb 0 x fragment to b 3 -null platelets was similarly decreased, whereas there was no detectable difference in binding of the W111I/F258W/I272A/ L386W mutant to WT and b 3 -null platelets (Fig. S3B,C) . Mean AE SEM, n ≥ 3, *P < 0.05, **P < 0.01, ANOVA. NS, non-significant; PBS, phosphate-buffered saline.
These data are consistent with the competitive binding assay results, confirming the importance of the b 0 domain in binding, with the a and a 0 domains contributing. The residual binding may represent binding to other platelet integrins (such as a 2 b 1 , which interacts with PDI [19] ), or other proteins (such as the secreted a-granule proteins vitronectin and thrombospondin-1, which interact with PDI [15, [20] [21] [22] ). As PDI binds poorly to Mn 2+ -treated b 3 -null platelets [3] and Mn 2+ does not induce secretion of agranule contents (measured by P-selectin expression [23] ), integrins probably provide the predominant binding partners for PDI on platelets.
Addition of PDI to platelets resulted in an increase in MPB labeling of thiols in a IIb and b 3 (Fig. 6) . However, addition of the W111I/F258W/I272A/L386W quadruple mutant did not result in an increase in MPB labeling. The MPB-labeled bands coincided with a IIb and b 3 on immunoblotting, and immunoprecipitated with an antibody against a IIb b 3 subunit but not with a control antibody (Fig. S4) . The enhanced thiol labeling with addition of PDI suggests that the interaction of PDI with a IIb b 3 is dependent on the a, b 0 and a 0 domains of PDI, and that PDI affects disulfide bonds in a IIb b 3 . These studies were performed with non-activated platelets, to which there is little binding of PDI, but it is possible that there is a low level of binding of PDI to a IIb b 3 . Different conformations of a IIb b 3 are found on non-activated platelets, and a small amount of a IIb b 3 is in an activated form [24, 25] . Additionally, the MPB labeling assay is sensitive, and a small amount of labeling can be detected in a proportion of a IIb b 3 molecules [26] . The abb 0 x fragment of PDI binds to platelets but inhibits aggregation, because it lacks the C-terminal active site (Fig. 4) . To study the mechanism of PDI binding in platelet accumulation in vivo, we used a laser-induced injury model. Infusion of the abb 0 x fragment into WT mice inhibited platelet accumulation in vivo, whereas the ab fragment lacking the b 0 domain did not (Fig. 7A,B ). This suggests that the b 0 domain has a role in binding of PDI to platelets in vivo.
Discussion
To catalyze thiol-disulfide exchange reactions in substrates, PDI must be able to bind to them [6] . Previous studies using isolated domains and constructs of PDI [7, 12] or PDI variants with point mutations [4, 17, 18] formed the basis for our study, in which we characterized PDI binding to a IIb b 3 on platelets. Whereas the earlier work on PDI binding to substrates and proteins was performed with cell lysates or purified proteins, the current studies are the first to examine the mechanism of PDI binding to a substrate on intact cells and in vivo. As there is little binding to non-activated platelets [3] , the binding sites for PDI on a IIb b 3 must be exposed, because the integrin undergoes conformational changes with activation. This is in keeping with changes in the conformation of the substrate being the principal means to regulate PDIsubstrate interactions [6] .
Using domain constructs of PDI, we found that the binding of PDI to a IIb b 3 on thrombin-activated platelets depends on the b 0 domain of PDI. PDI fragments that contain the b 0 domain bind to a IIb b 3 , whereas PDI fragments that lack this domain do not (Fig. 2B) . Additionally, the double b 0 mutant F258W/I272A had impaired binding to a IIb b 3 , confirming that the b 0 domain is essential for binding to a IIb b 3 on platelets. Consistent with this finding, small-molecule inhibitors called bepristats that bind to the hydrophobic pocket in the b 0 domain of PDI inhibit in vitro platelet aggregation and platelet accumulation in vivo [27] . Knowledge of the interactions of PDI with a IIb b 3 may help in the design of antithrombotic therapy that targets PDI [28] . Both the abb 0 x and b 0 xa 0 constructs of PDI inhibited binding of Alexa 488-labeled PDI to thrombin-activated platelets (Fig. 2B) . Binding of the abb 0 x construct is of interest, as this fragment does not fulfill the minimum requirement of binding to collagen prolyl 4-hydroxylase [14] . This suggests some differences between the specific interactions of PDI with a IIb b 3 and the interactions of PDI with collagen prolyl 4-hydroxylase. These differences in binding are not surprising, given the structural differences between a IIb b 3 and collagen prolyl 4-hydroxylase.
A second finding of these studies is that the a and a (Fig. 4B) . Together, these data suggest a role for binding sites in the a and a Representative MPB blots (A) and cumulative data of the ratio of MPB labeling to a IIb or b 3 protein (B) are shown. Mean AE standard error of the mean, n = 4, *P < 0.05, **P < 0.01, ANOVA. Labeling was performed by adding MPB (100 lM) to washed non-activated platelets. NS, non-significant; PBS, phosphate-buffered saline.
platelets, and in vivo platelet accumulation. On the other hand, the b 0 xa 0 fragment also binds to platelets but contains the a 0 active site and does not inhibit aggregation. The abb 0 x fragment probably binds to platelets and competes with endogenous platelet PDI, whereas the b 0 xa 0 fragment containing both the b 0 binding site and the functional active site of PDI binds and can itself support aggregation. The binding ability of the mutant PDIs also predicted the results obtained with platelet aggregation. The W111I/I272W/L386W mutant, which partially binds to platelets (Fig. 3B) , partially recovers aggregation (Fig. 3B,C) . The W111I/F258W/I272A/L386W mutant, which has no detectable binding, does not support platelet aggregation (Fig. 4A-D [9] . The abb 0 x fragment, which binds to platelets and inhibits platelet aggregation but lacks the a 0 binding site, also bound with high affinity to a IIb b 3 , although with a slightly higher K d than WT PDI (Fig. 5B) . The ab fragment and the W111I/F258W/ I272A/L386W mutant bound with much lower affinities. These findings parallel the binding of these PDI variants to thrombin-activated platelets, and confirm the role of the b 0 domain in binding to a IIb b 3 , with contributions from the a and a 0 domains. This is the first report to characterize PDI binding to a native substrate, i.e. a IIb b 3 . Three major conformations of a IIb b 3 have been described as this integrin transitions from a low-affinity resting conformation, to an intermediate-affinity conformation, and then to a high-affinity conformation [30] . A dynamic equilibrium exists between these conformations, with multiple additional intermediate structures. As there is little binding of PDI to non-activated platelets, PDI must bind after platelet activation initiates inside-out changes in a IIb b 3 . After binding, a PDI-catalyzed reaction facilitates conformational changes in a IIb b 3 leading to the high-affinity conformation of a IIb b 3 .
PDI-substrate binding is a complex process involving multiple binding sites on PDI for larger proteins [4, 5] , and we now show that this is true for interactions of PDI with native proteins. The combination of several loweraffinity substrate-binding sites within PDI provides a multiplicative effect, resulting in higher-affinity binding. Multiple binding sites in PDI with lower affinities would also facilitate PDI binding to substrate/partner proteins of different sizes, structures, or conformations, as well as the release of clients from PDI after the reaction cycle is completed [31] . Consistent with this concept, the relative contributions of these sites differed between Caenorhabditis elegans collagen prolyl 4-hydroxylase ab dimer and human a 2 b 2 tetramer formation [4] . Given the multiple intermediate conformations of a IIb b 3 during platelet activation, this is probably of special significance for the physiological function of PDI in thrombosis. It is likely that, for each specific intermediate conformation of a IIb b 3 , the binding sites in a, b 0 and a 0 contribute to different extents. As PDIs with some mutations that have a major effect on PDI binding to collagen prolyl 4-hydroxylase (W111I/I272W or I272W/L386W) [4] bound normally to activated platelets (Fig. 3B) , other binding sites in PDI may be required to regulate the binding of PDI to a IIb b 3 . Differences in the binding sites on PDI could explain how PDI interacts with native protein substrates undergoing dynamic changes associated with platelet activation or other events that occur in thrombosis [1] [2] [3] . Addendum L. Wang designed the project, performed research, analyzed the data, and wrote the manuscript. J. Zhou performed research, and collected and analyzed data. L. Wang and C. C. Wang helped with study design and interpretation, and edited the manuscript. D. W. Essex designed the project, supervised the research, analyzed the data, and wrote the manuscript. Fig. S1 . SDS gel electrophoresis of PDI fragments. Fig. S2 . SDS gel electrophoresis of PDI mutant proteins. Fig. S3 . Binding of Alexa 647-labeled WT PDI, abbʹx fragment and PDI W111I/F258W/I272A/L386W to the surfaces of thrombin-activated platelets. Fig. S4 . Confirmation of MPB labeling of a IIb b 3 .
